TABLE 2.
Interactions Among Selected FKBP5 Single-Nucleotide Polymorphisms (SNPs), Prebaseline Adverse Life Events, and the Risk of the First Occurrence of a Major Depressive Episode in 884 Young Community Subjects in a 10-Year Prospective Study
Additive Interaction Effect Between Prebaseline Adverse Life Event and Homozygosity for SNP Minor Allele on Incident Major Depressive Episode During Follow-Upb |
||||||
---|---|---|---|---|---|---|
Homozygous for Minor Allele Versus Heterozygous |
Homozygous for Minor Allele Versus Homozygous for Major Allele |
|||||
SNPa and Presence of Lifetime Adverse Event Preceding Baseline | Risk Difference in Percentage Pointsc | 95% CI | p | Risk Difference in Percentage Pointsc | 95% CI | p |
rs3800373 (CC/AC/AA) | ||||||
Any adverse life event | 13.0d | 3.2 to 22.7 | 0.009 | 7.0 | –7.6 to 21.6 | 0.35 |
Any separation event | 11.0d | 0.0 to 22.0 | 0.05 | 3.7 | –13.0 to 20.4 | 0.67 |
Any trauma | 15.3d,e,f | 9.0 to 21.6 | <0.001 | 15.2d,e,f | 8.0 to 22.3 | <0.001 |
Any severe trauma | 16.7d,e,f | 12.0 to 21.4 | <0.001 | 16.1d,e,f | 10.1 to 22.1 | <0.001 |
rs9296158 (AA/AG/GG) | ||||||
Any adverse life event | 13.0d | 3.7 to 22.4 | 0.006 | 6.4 | –7.9 to 20.6 | 0.39 |
Any separation event | 12.2d | 2.9 to 21.6 | 0.01 | 2.2 | –14.4 to 18.7 | 0.80 |
Any trauma | 12.3d | 3.5 to 21.2 | 0.006 | 14.0d,e,f | 6.4 to 21.7 | <0.001 |
Any severe trauma | 13.3d,e | 5.6 to 21.0 | <0.001 | 14.4d,e,f | 7.3 to 21.4 | <0.001 |
rs1360780 (TT/CT/CC) | ||||||
Any adverse life event | 12.7d | 3.1 to 22.4 | 0.009 | 6.1 | –8.2 to 20.5 | 0.40 |
Any separation event | 11.6d | 1.6 to 21.6 | 0.03 | 2.0 | –14.6 to 18.6 | 0.82 |
Any trauma | 12.7d,e | 4.1 to 21.2 | 0.003 | 14.0d,e,f | 6.4 to 21.6 | <0.001 |
Any severe trauma | 13.5d,e,f | 5.9 to 21.0 | <0.001 | 14.4d,e,f | 7.5 to 21.3 | <0.001 |
rs9470080 (TT/CT/CC) | ||||||
Any adverse life event | 11.6d | 1.3 to 21.8 | 0.03 | 2.4 | –13.6 to 18.3 | 0.78 |
Any separation event | 9.4 | –2.3 to 21.2 | 0.12 | –3.4 | –23.3 to 16.5 | 0.74 |
Any trauma | 13.1d,e,f | 5.2 to 21.0 | 0.001 | 13.2d,e,f | 5.3 to 21.1 | 0.001 |
Any severe trauma | 13.6d,e,f | 6.7 to 20.8 | <0.001 | 13.3d,e,f | 5.7 to 20.9 | <0.001 |
rs4713916 (AA/AG/GG) | ||||||
Any adverse life event | 18.0d,e,f | 10.2 to 25.7 | <0.001 | 15.2d | 3.3 to 27.1 | 0.02 |
Any separation event | 12.8d | 3.0 to 22.6 | 0.01 | 5.6 | –10.4 to 21.6 | 0.50 |
Any trauma | 15.9d,e,f | 10.6 to 21.2 | <0.001 | 16.6d,e,f | 11.3 to 21.9 | <0.001 |
Any severe trauma | 16.0d,e,f | 11.5 to 20.6 | <0.001 | 16.3d,e,f | 11.5 to 21.2 | <0.001 |
Minor allele is listed first, i.e., for rs3800373 the minor allele is C; for rs9296158 the minor allele is A; for rs1360780 the minor allele is T; for rs9470080 the minor allele is T; and for rs4713916 the minor allele is A.
A total of 159 individuals first met the DSM-IV criteria for a major depressive episode during follow-up. The reference group comprised the subjects without an incident major depressive episode during follow-up.
The amount by which the sum of the independent effects of an adverse life event (in the absence of the risk genotype, i.e., homozygosity for the minor allele) and the risk genotype (in the absence of adverse life events) is exceeded by the joint effect of both factors, i.e., an adverse life event in the presence of the risk genotype.
Significant risk difference (p<0.05) when controlled for age and gender.
Significant risk difference (p<0.05) when controlled for age and gender and after Bonferroni correction for multiple testing (two independent event conditions, five SNPs).
Significant risk difference (p<0.05) when controlled for age, gender, and baseline anxiety and substance use disorders and after Bonferroni correction for multiple testing (two independent event conditions, five SNPs).